Assessment of plasma CD3, CD4 and CD8 levels in β-thalassemic patients with different treatment modalities

Zamzam Hassan Mohammed, Gamal Baheeg Mohamed, Gehan Lotfy Abdelhakeem, Aliaa Mohammed Monir

Abstract


Background: β Thalassaemia major is one of the chronic hemolytic anemias resulting from defect in β globin chain. It requires frequent blood transfusion plus other treatment modalities. These treatment modalities may be associated with certain immunologic modulations. Objective: To assess various immunological parameters in β thalassemic children under different treatment modalities. Subjects and Methods: Forty-eight children were enrolled and classified into four groups. Twelve β thalassemic patients treated only with blood transfusion (group I). Twelve patients treated with transfusion and iron chelation (group II). Twelve patients treated with transfusion, iron chelation and subjected to splenectomy (group III). Group IV involved twelve healthy age and sex matched children. CBC plus serum levels of ferritin, were measured along with detection of CD3, CD4 and CD8 percentages. Results: Significant statistical differences regarding CD3, CD4 and CD8 T lymphocytes percentages within thalassemic groups when compared to each other’s and to healthy controls except for CD3 T lymphocytes in group II versus III. Splenectomized patients had higher significant levels regarding serum ferritin (p=0.02), CD4 (p=0.001), CD8 (p=0.001) and CD3 (p=0.001) compared to non splenectomized ones. Conclusion: Immune modulation occurs in thalassemic patients with regional specific variations. This may also be related to the difference in treatment modalities.

Keywords


Thalassaemia; Immunity; Treatment modalities

References


Cao A, Galanello R (2010) Beta-thalassemia. Genet Med 12: 61-76.

Alamiry A, Ali T, Majeed M (2011) Detection of hemoglobinopathies in

Hypochromic, Microcytic and Sickeled Cell Blood Films by Hemoglobin

Electrophoresis. Thi-Qar Med J 5: 139-148.

Weatherall DJ (2010) The inherited diseases of hemoglobin are an

emerging global health burden. Blood 115: 4331-4336.

Vento S, cainelli F, Cesario F (2006) Infections and thalassaemia. Lancet

Infect Dis 6: 226-233.

Alidoost F, Gharagozloo M, Bagherpour B, Jafarian A, Saj-Jadi SE, et al.

(2006) Effects of silymarin on the proliferation and glutathione levels of

peripheral blood mononuclear cells from beta-thalassemia major

patients. Int Immunopharmacol 6: 1305-1310.

Morabiton N, Russogt GT, Gaudio A, Lasco A, Catalano A, et al. (2007)

The “lively” cytokines network in beta-thalassemia major-related

osteoporosis. Bone 40: 1588-1594.

Sari TT, Gatot D, Akib AA, Bardosono S, Hadinegoro SR, et al. (2014)

Immune response of thalassemia major patients in Indonesia with and

without splenectomy. Acta Med Indones 46: 217-225.

Higgs DR, Engel JD, Stamatoyannopoulos G (2012) Thalassaemia. Lancet

: 373-383.

Gomes MP, Smedbol E, Chalifour A, Hénault-Ethier L, Labrecque M, et

al. (2014) Alteration of plant physiology by glyphosate and its by-product

aminomethylphosphonic acid: an overview. J Exp 65: 4691-4703.

Yu Q, Han H, Cawthray GR, Wang SF, Powles SB (2013) Enhanced rates

of herbicide metabolism in low herbicide-dose selected resistant Lolium

rigidum. Plant Cell Environ 36: 818-827.

Borgna-Pignatti C, Vergine G, Lombardo T, Cappellini MD, Cianciulli P,

et al. (2004) Hepatocellular carcinoma in the thalassaemia syndromes. Br

J Haematol 124: 114.

Asadov ChD (2014) Immunologic Abnormalities in β-Thalassemia. J

Blood Disorders Transf 5: 224.

Tubman VN, Fung EB, Vogiatzi M, Thompson AA, Rogers ZR, et al.

(2015) Guidelines for the Standard Monitoring of Patients

with Thalassemia: Report of the Thalassemia Longitudinal Cohort. J

Pediatr Hematol Oncol 37: 162-169.

Farmakis D, Giakoumis A, Polymeropoulos E, Aessopos A (2003)

Pathogenetic aspects of immune deficiency associated with betathalassemia.

Med Sci Monit 9: 19-22.

Capellini M, Cohen A, Eleftheriou A, Piga A, Porter J, et al. (2008)

Guidelines for the clinical management of thalassemia 2008. (2nd revised

edition), Nicosia.

Rahav G, Volach V, Shapiro M, Rund D, Rachmilewitz EA, et al. (2006)

Severe infections in thalassemic patients: prevalence and predisposing

factors. Br J Haematol 133: 667-674.

Ahluwalia J, Datta U, Marwaha RK, Sehgal S (2000) Immune functions in

splenectomised thalassemic children. Indian J Pediatr 67: 871-876.

Lee AC, Li CH (2004) Age as a factor in severe bacterial infection in

transfusion-dependent patients with thalassemia major. Clin InfectDis

: 1194-1195.

Gharagozloo M, Karimi M, Amirghofran Z (2009) Double-faced cellmediated

immunity in beta-thalassemia major: stimulated phenotype

versus suppressed activity. Ann Hematol 88: 21-27.

Noulsri E, Lerdwana S, Fucharden S, Pattanapanyasat K (2014)

Phenotypic characterization of circulating CD4/CD8 T-lymphocytes in

beta thalassemia patients. Asian Pac J Allergy Immunol 32: 261-269.

Moshtaghi-kashanian GR, Gholamhoseinian A, Hoseinimoghadam A,

Rajabalian S (2006) Splenectomy changes the pattern of cytokine

production in beta-thalassemic patients. Cytokine 35: 253-257.

Jeddoa, A, Saar JR, Adel AA (2011) Immunological Evaluation of Patients

with Β-Thalassemia Major in Kerbala City Using Single Radial

Immunodiffusion (SRID) Technique. Karbala J Med 4: 1-2.

Kiani-Amin M, Daneshi M, Ayazi P, Mohammadian S, Rezaei N (2011)

Serum immunoglobulin levels in splenectomized and nonsplenectomized

patients with major Beta-thalassemia. Iran J Pediatr 21:

-98.

Del Vecchio GC, Schettini F, Piacente L, De Santis A, Giordano P, (2002)

Effects of deferiprone on immune status and cytokine pattern in

thalassaemia major. Acta Haematologica 108: 144-149.

Consolini R, Calleri A, Legitimo A, Massei F (2001) Immunological

evaluation of patients with beta-thalassemia major. Acta Haematol 105:

-12.


Refbacks

  • There are currently no refbacks.